Dzenis Koca, Behnoush Abedi-Ardekani, Joel LeMaoult, Laurent Guyon
{"title":"瘤周组织 (PTT):越来越需要命名规范。","authors":"Dzenis Koca, Behnoush Abedi-Ardekani, Joel LeMaoult, Laurent Guyon","doi":"10.1038/s41416-024-02828-y","DOIUrl":null,"url":null,"abstract":"Various terms are used to describe non-malignant tissue located in the proximity of a tumor, belonging to the organ from which the tumor originated. Traditionally, these tissues, sometimes called “normal adjacent tissue” have been used as controls in cancer studies, and were considered representative of morphologically healthy, non-cancerous tissue. However, with the advancement of OMIC technologies, such tissues are increasingly recognized to be distinct from both tumor and healthy tissues. Furthermore, properties, characteristics, and role of these tissues in cancer formation and progression is increasingly studied. In order to make future research in this area more harmonized and more accessible, as well as to counter the widespread perception of normalcy, we are advocating the need for standardized naming convention. For this purpose, we propose the use of neutral and comprehensive term “Peritumoral Tissue” along with the acronym “PTT”. While significant amount of data on these tissues are publicly available, reuse of such data remains limited due to a lack of information on sample collection procedures. In order to facilitate future reuse of the data, we suggest a list of features that should be documented during sample collection procedures. These recommendations can aid the definition of Standard Operating Procedures.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02828-y.pdf","citationCount":"0","resultStr":"{\"title\":\"Peritumoral tissue (PTT): increasing need for naming convention\",\"authors\":\"Dzenis Koca, Behnoush Abedi-Ardekani, Joel LeMaoult, Laurent Guyon\",\"doi\":\"10.1038/s41416-024-02828-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Various terms are used to describe non-malignant tissue located in the proximity of a tumor, belonging to the organ from which the tumor originated. Traditionally, these tissues, sometimes called “normal adjacent tissue” have been used as controls in cancer studies, and were considered representative of morphologically healthy, non-cancerous tissue. However, with the advancement of OMIC technologies, such tissues are increasingly recognized to be distinct from both tumor and healthy tissues. Furthermore, properties, characteristics, and role of these tissues in cancer formation and progression is increasingly studied. In order to make future research in this area more harmonized and more accessible, as well as to counter the widespread perception of normalcy, we are advocating the need for standardized naming convention. For this purpose, we propose the use of neutral and comprehensive term “Peritumoral Tissue” along with the acronym “PTT”. While significant amount of data on these tissues are publicly available, reuse of such data remains limited due to a lack of information on sample collection procedures. In order to facilitate future reuse of the data, we suggest a list of features that should be documented during sample collection procedures. These recommendations can aid the definition of Standard Operating Procedures.\",\"PeriodicalId\":9243,\"journal\":{\"name\":\"British Journal of Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/s41416-024-02828-y.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41416-024-02828-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41416-024-02828-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Peritumoral tissue (PTT): increasing need for naming convention
Various terms are used to describe non-malignant tissue located in the proximity of a tumor, belonging to the organ from which the tumor originated. Traditionally, these tissues, sometimes called “normal adjacent tissue” have been used as controls in cancer studies, and were considered representative of morphologically healthy, non-cancerous tissue. However, with the advancement of OMIC technologies, such tissues are increasingly recognized to be distinct from both tumor and healthy tissues. Furthermore, properties, characteristics, and role of these tissues in cancer formation and progression is increasingly studied. In order to make future research in this area more harmonized and more accessible, as well as to counter the widespread perception of normalcy, we are advocating the need for standardized naming convention. For this purpose, we propose the use of neutral and comprehensive term “Peritumoral Tissue” along with the acronym “PTT”. While significant amount of data on these tissues are publicly available, reuse of such data remains limited due to a lack of information on sample collection procedures. In order to facilitate future reuse of the data, we suggest a list of features that should be documented during sample collection procedures. These recommendations can aid the definition of Standard Operating Procedures.
期刊介绍:
The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.